Telavancin drug interactions: Difference between revisions
Created page with "__NOTOC__ {{Telavancin}} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIBATIV (TELAVANCIN HYDROCHLORIDE) INJECTION..." |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Drug Interactions== | |||
===Drug-Laboratory Test Interactions=== | |||
====Effects of Telavancin on Coagulation Test Parameters==== | |||
Telavancin binds to the artificial phospholipid surfaces added to common anticoagulation tests, thereby interfering with the ability of the coagulation complexes to assemble on the surface of the phospholipids and promote clotting in vitro. These effects appear to depend on the type of reagents used in commercially available assays. Thus, when measured shortly after completion of an infusion of VIBATIV, increases in the PT, INR, aPTT, and ACT have been observed. These effects dissipate over time, as plasma concentrations of telavancin decrease. | |||
====Urine Protein Tests==== | |||
Telavancin interferes with [[urine qualitative]] dipstick protein assays, as well as quantitative dye methods (e.g., pyrogallol red-molybdate). However, [[microalbumin]] assays are not affected and can be used to monitor urinary protein excretion during VIBATIV treatment.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIBATIV (TELAVANCIN HYDROCHLORIDE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ASTELLAS PHARMA US INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5e7c066c-0950-47ce-899d-76881d80c492 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 00:00, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Drug Interactions
Drug-Laboratory Test Interactions
Effects of Telavancin on Coagulation Test Parameters
Telavancin binds to the artificial phospholipid surfaces added to common anticoagulation tests, thereby interfering with the ability of the coagulation complexes to assemble on the surface of the phospholipids and promote clotting in vitro. These effects appear to depend on the type of reagents used in commercially available assays. Thus, when measured shortly after completion of an infusion of VIBATIV, increases in the PT, INR, aPTT, and ACT have been observed. These effects dissipate over time, as plasma concentrations of telavancin decrease.
Urine Protein Tests
Telavancin interferes with urine qualitative dipstick protein assays, as well as quantitative dye methods (e.g., pyrogallol red-molybdate). However, microalbumin assays are not affected and can be used to monitor urinary protein excretion during VIBATIV treatment.[1]
References
Adapted from the FDA Package Insert.